Connect your AI

Wave Life Sciences WVE Book value per share

Book value per share at other companies

Eli LillyLLY

$34.82+98.9%

Sarepta Therapeutics, Inc.SRPT

$11.74+21.0%

Ionis PharmaceuticalsIONS

$2.98-0.6%

Madrigal Pharmaceuticals, Inc.MDGL

$18.72-26.0%

ALN

Alnylam PharmaceuticalsALNY

$7.78+137%

Beam TherapeuticsBEAM

$11.28-12.2%

Other financials

Income statement

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Profitability

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

total stockholders equity/weighted shares diluted=$2.56

Based on the most recent quarter.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Wave Life Sciences's book value per share?: Wave Life Sciences (WVE) reported book value per share of $2.56 in Q1 2026.
How has Wave Life Sciences's book value per share changed year-over-year?: Wave Life Sciences's book value per share increased by 141.9% year-over-year, from $1.06 to $2.56.
What is the long-term trend for Wave Life Sciences's book value per share?: Over 5 years (2020 to 2025), Wave Life Sciences's book value per share has grown at a 7.8% compound annual growth rate (CAGR), from $2.11 to $3.07.
What does book value per share mean?: Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.